Metsera, Inc. Common Stock (MTSR NASDAQ) stock market data APIs
$52.6454
0.43(0.8%)
as of October 15, 2025
Try our APIs with
free plan!
Metsera, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
Prev. Close
52.6454
Open
53.0717
High
52.873
Low
52.0607
52 wk Range
12.3-54.47
Market Cap
4 124 M
Shares Outstanding
105 M
EPS
-0.6551
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Metsera, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Metsera, Inc. Common Stock data using free add-ons & libraries
Get Metsera, Inc. Common Stock Fundamental Data
Metsera, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -178 196 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-29
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Metsera, Inc. Common Stock News
New
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
After a muted start to 2025, Big Pharma is back on the M&A trail. In just a month, three major players — Pfizer PFE, Novo Nordisk NVO and Roche RHHBY — announced multi-billion-dollar deals targeti...
Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock
Pfizer Inc. (NYSE:PFE) is included among the 12 Best Dividend Stocks with Yields Above 4%.Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock Pfizer Inc. (NYSE:PFE) is a...
Where Will Pfizer Be in 5 Years?
Key Points Pfizer is one of the world's largest pharmaceutical companies. It has a few material patent expirations on the horizon. It's doing what it has to do to deal with that headwind and others. ...
Why Biotech’s Rally Can Last This Time
After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus. Whether the run continues will depend on several factors: continued funding, a pre...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
